1. Analysis of first plus recurrent cardiovascular (CV) and hospitalisation events in the CAROLINA trial. (25th November 2020) Authors: Marx, N; McGuire, D.K; Johansen, O.E; Rosenstock, J; Pfarr, E; Mattheus, M; George, J.T; Espeland, M.A; Zinman, B Journal: European heart journal Issue: Volume 41:(2020)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Fetal sex and maternal risk of pre‐eclampsia/eclampsia: a systematic review and meta‐analysis. (17th June 2016) Authors: Jaskolka, D; Retnakaran, R; Zinman, B; Kramer, CK Journal: BJOG Issue: Volume 124:Number 4(2017) Page Start: 553 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Impact of changes in weight and haematocrit on the reduction in systolic office and ambulatory blood pressure with empagliflozin in patients with type 2 diabetes. (14th October 2021) Authors: Sharma, A; Wanner, C; Ofstad, A P; Mattheus, M; Kraus, B J; Zinman, B; Ferreira, J P Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Impact of polyvascular disease and renal dysfunction on cardiovascular outcomes in diabetes: post hoc analyses from EMPA-REG OUTCOME. (25th November 2020) Authors: Verma, S; Mazer, C.D; Inzucchi, S.E; Wanner, C; Ofstad, A.P; Johansen, O.E; Zwiener, I; George, J.T; Butler, J; Zinman, B Journal: European heart journal Issue: Volume 41:(2020)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Obstructive sleep apnoe and cardiovascular, heart failure and mortality outcomes with empagliflozin versus placebo in the EMPA-REG OUTCOME trial. (25th November 2020) Authors: Yaggi, H.K; Eliasson, B; Kasai, T; Marx, N; Zinman, B; Inzucchi, S.E; Wanner, C; Zwiener, I; Wojeck, B; Neeland, I; Johansen, O Journal: European heart journal Issue: Volume 41:(2020)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P1879Empagliflozin reduces mortality and hospitalisation for heart failure irrespective of cardiovascular risk score at baseline. (28th August 2018) Authors: Fitchett, D; Inzucchi, S E; Cannon, C P; McGuire, D K; Johansen, O E; Sambevski, S; Hehnke, U; George, J; Zinman, B Journal: European heart journal Issue: Volume 39(2018)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P5334Effect of empagliflozin on cardiovascular events including recurrent events in the EMPA-REG OUTCOME trial. (28th August 2018) Authors: McGuire, D K; Zinman, B; Inzucchi, S E; Anker, S D; Wanner, C; Kaspers, S; George, J T; Elsasser, U; Woerle, H J; Lund, S S; Fitchett, D Journal: European heart journal Issue: Volume 39(2018)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗